NANOG and cancer: However, GTPBP2 ablation or overexpression could not affect the expression of NANOG and other stemness markers in CD133−CD44− and CD133−CD44+ cells, suggesting that GTPBP2 no longer regulates stemness in non-CCSC cancer cells probably due to altered intracellular microenvironment.